Actually, this vaccine is in phase III clinical trials in association with sargramostim, a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF), normally used to cure neutropenia caused by chemotherapy during the AML treatment (source http://www.clinicaltrials.gov). Here, CSF2 is linked to neutropenia.